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UTERINE EMBOLIZATION FOR MANAGEMENT OF SYMPTOMATIC
FIBROIDS: QUALITY-OF-LIFE IMPACT*
Nestor Kisilevzky1
OBJECTIVE: To determine the impact on the quality of life in patients with symptomatic uterine fibroids
submitted to uterine artery embolization. MATERIALS AND METHODS: Forty patients with symptomatic fi-
broids submitted to embolization have answered a quality-of-life questionnaire before and 12 weeks after
the procedure. RESULTS: Mean score for symptoms severity before the procedure was 62.07 ± 6.34 and
decreased with statistical significance to 20.42 ± 3.81 after the procedure. Similarly, scores for quality of
life have improved from 40.26 ± 2.98 before the procedure to 85.06 ± 2.57 after the procedure, which
again was statistically significant. CONCLUSION: Uterine embolization results in evident symptoms relief
and significant improvement in the quality of life of patients with symptomatic fibroids.
Keywords: Therapeutic embolization; Uterus; Leiomyoma; Quality of life; Interventional radiology.
Embolização uterina para tratamento de miomas sintomáticos: impacto na qualidade de vida.
OBJETIVO: Verificar a mudança na qualidade de vida de pacientes portadoras de miomatose uterina sinto-
mática submetidas a tratamento por embolização. MATERIAIS E MÉTODOS: Quarenta mulheres portadoras
de miomatose uterina sintomática que foram tratadas com a técnica de embolização responderam a um
questionário de qualidade de vida antes e 12 semanas após o procedimento. RESULTADOS: Verificou-se
que o escore médio relacionado com a gravidade dos sintomas nas 40 pacientes antes da embolização foi de
62,07 ± 6,34 e se modificou, com significância estatística após o tratamento, quando se verificou escore
médio de 20,42 ± 3,81. Da mesma forma, comprovou-se a melhora na qualidade de vida pela modificação
dos escores antes e depois do tratamento, o que também apresentou significância estatística, passando de
40,26 ± 2,98 para 85,06 ± 2,57. CONCLUSÃO: A embolização uterina provoca alívio evidente dos sinto-
mas relacionados com a miomatose e proporciona melhora substancial da qualidade de vida das pacientes.
Unitermos: Embolização terapêutica; Útero; Leiomioma; Qualidade de vida; Radiologia intervencionista.
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INTRODUCTION
Uterine myomas, also called leiomy-
omas or fibroids, are the most common
benign gynecologic tumors, and may be
present in up to 40% of women in child-
bearing age(1).
Most frequently, myomatosis affects
nulliparous, obese, black women, or those
with family history of myomatosis or
hyperestrogenic syndrome(2).
Despite the absolutely benign nature of
myomas, complaints of uncomfortable
symptoms such as menorrhagia (abnormal
menstrual bleeding), dysmenorrhea (pain-
ful menstruation), a felling of pressure in
the pelvis, increase in the urinary fre-
quency, pain, infertility or increase in ab-
dominal volume and palpable pelvic mass
are very frequent(3).
Clinical presentation is variable and is
particularly related to the size, location and
number of myomas, but certainly myoma-
tosis symptoms, when present, result in a
remarkable impairment of the patients’
quality of life.
The most frequent symptom is an abnor-
mal uterine bleeding (menorrhagia) that
usually is characterized by increased men-
strual duration and blood flow volume,
sometimes leading to anemia(4). Generally,
women complain of a progression in the
intensity, that is to say, a gradual increase
in the menstrual blood flow obliging them
to more frequent tampon or pad changes,
or even to the use of diapers during the
period. It is in these circumstances where
women report that they avoid leaving
home, scheduling professional or social
activities because of the discomfort caused
by the menstruation, or in order to avoid
embarrassing or upsetting situations.
Until recently, only two therapeutic
modalities were available for treating
symptomatic myomatosis: the surgical ap-
proach or hormone therapy.
Definitely, hysterectomy is the most
commonly performed procedure for the
management of myomatosis. It is estimated
that myomatosis accounts for one third of
almost 400,000 hysterectomies performed
in the United States of America(5). Despite
the advantage of being definitely curative,
hysterectomy is a formal surgical procedure
that requires hospital stay for some days
and a variable period of postoperative re-
covery and convalescence. Also, hysterec-
tomy may be associated to a considerable
blood loss, ureter injury, prolapse and other
complications(6). Besides, it eliminates any
possibility of fertility, which represents a
deep loss for nulliparous women.
Starting in 1991, a team of French doc-
tors started the clinical utilization of uter-
ine embolization as an alternative for treat-
ing uterine fibroids. The early results of
these experiments were published in 1995
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by the prestigious journal The Lancet, em
1995, suggesting that this was a highly ef-
ficient method for the management of uter-
ine myomatosis symptoms(7).
Since that time, numerous clinical ex-
periments have been reported worldwide,
demonstrating the validity of this promis-
ing percutaneous procedure(8–15).
Uterine embolization is a minimally
invasive modality of interventional radiol-
ogy that consists in intentionally blocking
the arteries that supply blood to the fi-
broids, causing their ischemia and shrink-
age, resulting in the resolution of their
symptoms. For this purpose, a thin catheter
is inserted under local anesthesia, by means
of puncture of the femoral artery in the in-
guinal region, and, under fluoroscopic vi-
sion generated by a digital angiography
apparatus, the catheter is inserted and ad-
vanced to the uterine arteries. Gelatin
microspheres measuring about 500-µ is
then injected through the angiographic
catheter until stasis of the branches that
supply blood to the fibroids(16).
Since we started applying this technique
in Brazil, in 1999, we have already treated
450 patients. Technical and clinical out-
comes from this initial experiment have
been previously published(17).
The present study reports outcomes
from a group of patients submitted to uter-
ine embolization, utilizing a system for
evaluation and comparison of their quality
of life before and after the treatment.
MATERIALS AND METHODS
The present study evaluated data ob-
tained from images and questionnaires
answered by 40 women with symptomatic
uterine myomatosis who were submitted to
uterine embolization in the period between
July/2004 and June/2006, in the Division
of Interventional Radiology at Hospital
Santa Catarina in São Paulo, SP, Brazil.
The analysis included data from women
with complaints resulting from the pres-
ence of uterine fibroids who, during the
preoperative clinical evaluation and the
period of postoperative clinical follow-up
had answered a questionnaire about qual-
ity of life related to the disease treated. The
mean age of patients was 38 years (age
range = 22 – 46 years). As regards the pa-
tients’ race, 31 women were Caucasian,
five were black, and four Asian. The pa-
tients’ gestational history showed that 28 of
them were multiparous, and 12 were nul-
liparous. Amongst the patients included in
the present study, 28 reported a job or pro-
fessional activity, and 12 defined their ac-
tivity as “housewives”. The main complaint
leading to the treatment was increased
menstrual bleeding, with or without anemia
in 29 patients, and pain or compressive
symptoms secondary to uterine increase in
11. The diagnosis of uterine myomatosis
was based on data collected from the clini-
cal history, clinical examination and pelvic
magnetic resonance imaging or ultrasound.
All of the pre- and postoperative image
studies were performed in an ambulatorial
setting in different divisions of the hospi-
tal where the patients were submitted to the
treatment. All the patients presented with
increased uterine volume (mean = 666 cm³,
ranging between 245 cm³ and 1.930 cm³).
The method included puncture of the right
femoral artery, angiographic study of uter-
ine arteries, and embolization with cali-
brated 500–700-µ spheres (Embosferas®).
The procedures were documented by
means of pre- and post-embolization
angiographic studies (Figure 1).
All the patients remained hospitalized
24 hours for rest and observation.
At the time of the preprocedural clini-
cal evaluation, all the patients answered a
questionnaire for evaluation of their qual-
ity of life related to the presence of fibroids
(Chart 1). This questionnaire was specifi-
cally developed for this purpose in the
Georgetown University, Washington,
USA(18), and translated into Portuguese by
a professional translator. It includes 37
questions, and is divided into two parts.
The first one includes eight questions about
the intensity or severity of symptoms re-
ported by the patient. Each of these ques-
tions offer five options corresponding to
intensity: “no”, “little”, “reasonable”,
“much”, “very much”, with a correspond-
ing scoring from 1 to 5. The final scoring
is converted into a corrected score by
means of a mathematical formula. The sec-
ond part of the questionnaire includes 29
Figure 1. Standard angiographic documentation of uterine embolization procedure: A: Selective cath-
eterization of right uterine artery. Intrauterine branches can be observed delimitating nodular areas. B:
Left-sided selective catheterization with angiographic aspect similar to the right side. C: After emboliza-
tion, disappearance of the branches that supply blood to the fibroids, with main intrauterine branches
preserved. Also, a preserved right ovarian artery is observed with ascending course (arrow). D: After
embolization, main branches and left ovarian artery are preserved (arrow).
A
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B
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Chart 1 Quality-of-life questionnaire utilized in the present study.
QUALITY-OF-LIFE QUESTIONNAIRE RELATED TO UTERINE FIBROIDS.
The following items correspond to common symptoms experienced by women affected by uterine fibroids. Please, consider each of these symptoms as
being related to the presence of fibroids or to your menstrual cycle. Each of the questions is related to the level and intensity of anguish or discomfort you
have experienced as a result of these symptoms during the last three months.
There is no correct or wrong answer. Simply choose an option which best fits your symptoms that has led you to seek for the treatment (indicate by marking
X on the appropriate site).
During the last three months, what has been the level of discomfort caused by...
1. Heavy bleeding during menstruation.
2. Clots in the menstrual flow.
3. Alteration in the period duration as compared to previous periods.
4. Alteration in the interval between periods as compared to the past.
5. Feeling of pressure or tension in the pelvis.
6. Frequent necessity to urinate in the daytime.
7. Frequent necessity to urinate at night.
8. Feeling of fatigue.
No

1

1

1

1

1

1

1

1
Little

2

2

2

2

2

2

2

2
Reasonable

3

3

3

3

3

3

3

3
Much

4

4

4

4

4

4

4

4
Very much

5

5

5

5

5

5

5

5
The questions below relate to the impact caused by the fibroids symptoms intensity on your life. Please, consider each of these questions as being exclu-
sively related to the presence of fibroids during the last three months.
There is no correct or wrong answer. Simply choose an option which best fits your symptoms that has led you to seek for the treatment (indicate by marking
X on the appropriate site). If no option fits your experience, select “at no time” (1).
Most
of time

4

4

4

4

4

4

4

4

4

4

4

4

4

4
During the last three months, with which frequency symptoms caused by
fibroids...
At no
moment

1

1

1

1

1

1

1

1

1

1

1

1

1

1
Few
times

2

2

2

2

2

2

2

2

2

2

2

2

2

2
Some
times

3

3

3

3

3

3

3

3

3

3

3

3

3

3
All
the time

5

5

5

5

5

5

5

5

5

5

5

5

5

5
9. Have caused anxiety because of the unpredictability of the amount and duration
of your menstrual period?
10. Have caused preoccupation with a travel?
11. Have affected your physical activities?
12. Have caused tiredness?
13. Have made you to reduce the amount of time spent on exercises or physical
activities?
14. Have made you feel like you were not in control of your own life?
15. Have caused a fear that you might stain your underwear?
16. Have made you feel less productive?
17. Have caused somnolence in the daytime?
18. Have cause embarrassment because of overweight?
19. Have made you feel difficulty in your daily activities?
20. Have affected your social activities?
21. Have made you feel uncomfortable with the size of your abdomen?
22. Have caused fear that you might stain your bed linen?
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23. Have made you feel sad, discouraged or desperate?
24. Have made you feel depressed?
25. Have made you “feel like a wet rag”?
26. Have caused preoccupation with your health?
27. Have made you to plan your activities more carefully?
28. Have made you feel bothered to carry pads and additional cloths to prevent
accidents?
29. Have made you experience embarrassing situations?
30. Have caused uncertainty about the future?
31. Have caused irritation?
32. Have caused a fear that you might stain your external clothes?
33. Have affected the size of your clothes during your periods?
34. Have made you feel like you were not in the control of your health?
35. Have made you feel tiredness like the energy had been sucked out of you?
36. Have caused a decrease in your sexual desire?
37. Have made you to avoid having sexual relations?
Most
of time

4

4

4

4

4

4

4

4

4

4

4

4

4

4

4
During the last three months, with which frequency symptoms caused by
fibroids...
At no
moment

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1
Few
times

2

2

2

2

2

2

2

2

2

2

2

2

2

2

2
Some
times

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3
All
the time

5

5

5

5

5

5

5

5

5

5

5

5

5

5

5
Chart 1 Quality-of-life questionnaire utilized in the present study. (Continued).
Calculation of quality of life related to the presence of fibroids
1 – Calculation of the symptoms severity (higher value = higher severity — scale 1 to 100)
Scale
Symptom severity
Summation – items
Sum up the values obtained in 1 to 8
Possible values < e >
8; 40
Possible options
32
Formula:
Converted score = (current score – < possible score) × 100
Possible options
2 – Calculation by category and general quality of life
Scale
Preoccupation
Activity
Mood/energy
Self-control
Embarrassment
Sexuality
Total quality of life
Results summation items
9 + 15 + 22 + 28 + 32
10 + 11 + 13 + 19 + 20 + 27 + 29
12 + 17 + 23 + 24 + 25 + 31 + 35
14 + 16 + 26 + 30 + 34
18 + 21 + 33
36 + 37
Summation
Possible values < e >
5; 25
7; 35
7; 35
5; 25
3; 15
2; 10
29; 145
Possible options
20
28
28
20
12
8
116
Formula for calculation of quality of life — higher value = higher quality of life — scale 1 to 100
Score = (> possible score – current score) × 100
Possible options
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questions about the frequency in which the
fibroids symptoms affect aspects of the
patients’ daily lives. These questions are
divided into groups corresponding to six
aspects: preoccupation, activity, mood/en-
ergy, self-control, embarrassment, and
sexuality. Each of these questions offers
five answering options to measure fre-
quency: “at no time”, “few times”, “some-
times”, “most of time” and “all the time”,
with a corresponding scoring from 1 to 5.
The final score is converted into a corrected
score by means of a mathematical formula.
In the first part, the questionnaire pre-
sents the evaluation of symptoms intensity
stratified from 0 to 100, meaning that 100
corresponds to the highest intensity or se-
verity of the patients complaint. The sec-
ond part evaluates the quality-of-life itself,
i.e. the health condition expressed by a
stratified scoring from 0 to 100, where 100
corresponds to the best level of quality-of-
life in general, and for each of the specific
aspects investigated by the questionnaire.
During the 12-week follow-up period
following the procedure, the patients were
submitted to a pelvic magnetic resonance
imaging for evaluating the uterine size as
compared to the similar study previously
performed. Also, they were asked to, again,
answer the quality-of-life questionnaire.
Data obtained from questionnaires an-
swers as well as those concerning the uter-
ine volumes evaluated by magnetic reso-
nance imaging were transcribed into a
Microsoft Excel worksheet for statistical
analysis. Initially, all of the variables were
descriptively analyzed. As for quantitative
variables, this analysis was performed
through observation of minimum and
maximum values, as well as calculation of
median and standard deviation. As for
qualitative variables, absolute and relative
frequencies were calculated. The paired
Student’s t test was utilized for analysis of
premoment x postmoment equality hypoth-
esis; when the data normality assumption
was rejected, the non-parametric Wilcoxon
test was utilized. The significance level
utilized for these tests was 5%.
The present study was submitted to the
Committee for Ethics in Research of do
Hospital Santa Catarina, whose approval
(Process CEP019/06) has established that
the study was conducted in compliance
with the Resolution 196/96 of Conselho
Nacional de Saúde (National Council of
Health).
RESULTS
All of the statistical variables evaluated
before and after the procedure are shown
on Table 1.
Mean uterine volume measured by post-
embolization magnetic resonance imaging
was 450 cm³, corresponding to a statisti-
cally significant decrease in volume of
32.5% (Figures 2 and 3).
The mean score related to symptoms
intensity reported in the preprocedural
quality-of-life questionnaires was 62.07.
The postprocedural quality-of-life ques-
tionnaires demonstrated a statistically sig-
nificant decrease in the mean score to
20.42, representing a 67.1% improvement
in symptoms.
The analysis of total quality of life
(health condition) related to the patients’
myomatosis showed postprocedural score
of 40.26, that changed substantially after
the treatment, achieving 85.06. This was
statistically significant, representing an
improvement of 52.6% in the patients’
quality of life (Figure 4).
All the items evaluated by the question-
naire demonstrated changes after the treat-
ment (Figure 5).
Mean score related to “preoccupation”
in the preprocedural questionnaires was
37.87. In the post procedural question-
naires this score changed to 83.5, showing
a statistically significant difference, and
corresponding to an improvement of 54.6%
in this item.
Mean score related to “activity” in the
preprocedural questionnaires was 43.53. In
the postprocedural questionnaires, this
score changed to 85.49, showing a statis-
Table 1 Mean, standard deviation, minimum, maximum values and median of variables in pre- and postprocedural evaluation of 40 patients.
Variable
Uterine volume
Symptoms
Preoccupation
Activity
Mood/energy
Self-control
Embarrassment
Sexuality
Quality of life
Moment
Pre
Post
Pre
Post
Pre
Post
Pre
Post
Pre
Post
Pre
Post
Pre
Post
Pre
Post
Pre
Post
n
40
40
40
40
40
40
40
40
40
40
40
40
40
40
40
40
40
40
Mean
666.03
449.95
62.07
20.42
37.88
83.50
43.53
85.40
44.09
85.49
39.75
84.88
36.61
85.78
28.44
83.75
40.27
85.06
SD
418.70
289.64
6.34
3.81
8.16
5.45
4.12
4.37
3.74
4.11
6.79
3.30
6.77
8.26
8.00
7.05
2.98
2.58
Minimum
245.00
168.00
46.80
9.30
10.00
65.00
28.50
71.40
28.50
71.40
25.00
80.00
16.20
58.30
12.50
62.50
33.60
76.70
Maximum
1930.00
1350.00
78.10
28.10
45.00
95.00
46.60
89.20
46.60
89.20
60.00
90.00
41.60
91.60
37.50
87.50
44.80
8.70
Median
495.00
357.50
62.50
20.25
40.00
85.00
42.80
85.70
46.60
85.70
40.00
85.00
41.60
91.60
25.00
87.50 
40.50
85.30
p
< 0.001*
< 0.001†
< 0.001†
< 0.001†
< 0.001†
< 0.001†
< 0.001†
< 0.001†
< 0.001†
* Descriptive level of probability of the paired t test. † Descriptive level of probability of the Wilcoxon non-parametric test. SD, standard deviation.
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Figure 3. Pre-embolization (A) and postembolization magnetic resonance imaging (sagittal view) dem-
onstrating complete ischemia of subserous and significant decrease in uterine volume.
A B
the postprocedural questionnaires, this
score changed to 83.55, showing a statis-
tically significant difference, and corre-
sponding to an improvement of 65.97%.
DISCUSSION
Since the publication of the first scien-
tific study on uterine embolization in 1995,
much has been learned about this theme.
The huge amount of papers published and
studies presented in international con-
gresses in the last ten years constitute un-
equivocal scientific evidence that uterine
embolization is an effective and safe method
for treating symptomatic fibroids, repre-
senting a dominant therapy for symptom-
atic myomatosis. Up to the present mo-
ment, it is estimated that more than 200,000
patients have already been treated world-
wide by means of uterine embolization.
Besides being safe and effective in the
management of myomatosis symptoms, the
method has already proved to present some
additional advantages.
Considering that this is a minimally in-
vasive, percutaneous method performed
under local anesthesia, it allows a rapid
clinical recuperation and quick recovery of
normal daily activities of the patients. A
study developed in Canada and published
in 2003, including more than 550 women,
demonstrated that 82% of patients submit-
ted to uterine embolization have a single-
day hospital stay(19).
Another study developed in the United
States of America and published in 2004
tically significant difference, and corre-
sponding to an improvement of 49% in this
item.
Mean score related to “mood/energy” in
the preprocedural questionnaires was
44.01. In the postprocedural question-
naires, this score changed to 85.39, show-
ing a statistically significant difference, and
corresponding to an improvement of
48.52% in this aspect.
Mean score related to “self-control” in
the preprocedural questionnaires was
39.75. In the postprocedural question-
naires, this score changed to 84.87, show-
ing a statistically significant difference, and
corresponding to an improvement of
53.31% in this item.
Mean score related to “embarrassment”
in the preprocedural questionnaires was
36.60. In the postprocedural question-
naires, this score changed to 85.78, show-
ing a statistically significant difference, and
corresponding to an improvement of
57.33% in this item.
Mean score related to “sexuality” in the
preprocedural questionnaires was 28.43. In
Figure 2. Statistical representation, comparing preprocedural and postprocedural uterine volumes.
Figure 4. Representation of mean scores and standard deviation of preprocedural and postprocedural
symptoms and quality of life.
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reported that 94% of patients submitted to
uterine embolization lost less than ten
working days, and that about 90% of
women fully recovered their activities
within two - three weeks following the pro-
cedure(20).
Uterine embolization advantages be-
come more evident in a comparison be-
tween results from hysterectomy and uter-
ine embolization. A randomized study de-
veloped in Spain, comparing results from
hysterectomy and uterine embolization, has
evidenced that embolization results in
shorter hospital stay, quicker clinical recov-
ery, and lower incidence of complica-
tions(21).
Besides the mentioned advantages, the
embolization impact on the patients´ qual-
ity of life must be taken into consideration.
The questionnaire utilized in the present
study was based on a survey involving both
healthy women and other affected by symp-
tomatic myomatosis. So, the idea was to
create a simple tool for evaluating the im-
pairment to the quality of life from the
point-of-view of the patients. This study is
the first to report the application of this type
of questionnaire to Brazilian women. Be-
sides being evident per se, the results are
very similar to those presented by interna-
tional studies.
A North-American study involving has
shown a 35% improvement in symptoms
and quality of life in 64 patients(22).
The largest multicentric study ever de-
veloped in the world including more than
2 thousand patients submitted to uterine
embolization has demonstrated that the
symptoms intensity score evaluated by the
quality-of-life changed from 59 before the
procedure to 20 after the treatment. The
same study has shown that the patients´
quality of life improved from 47 to 87
points(23).
Uterine embolization benefits and ad-
vantages are translated into a very high rate
of satisfaction reported by patients submit-
ted to this treatment. A recently published
Dutch study has shown that, 36% of 158
women submitted to embolization declared
to be “satisfied”, and 57% “very satisfied”
with this modality of treatment(24).
CONCLUSION
Uterine embolization is a minimally
invasive and effective method for alleviat-
ing the uncomfortable symptoms caused by
fibroids. The utilization of a quality-of-life
questionnaire has resulted in a simple and
effective tool for demonstrating the im-
provement in symptoms and in quality of
life as a whole.
Uterine embolization becomes a highly
significant method for treating women who
wish to preserve their uteri, or those who
need to quickly recover their normal activi-
ties after the treatment.
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